Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €66.97 EUR
Change Today -0.90 / -1.32%
Volume 0.0
JUD On Other Exchanges
Symbol
Exchange
Berlin
As of 3:54 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

st jude medical inc (JUD) Snapshot

Open
€67.43
Previous Close
€67.87
Day High
€67.70
Day Low
€65.97
52 Week High
07/20/15 - €71.16
52 Week Low
10/15/14 - €44.00
Market Cap
18.8B
Average Volume 10 Days
149.4
EPS TTM
--
Shares Outstanding
281.2M
EX-Date
06/26/15
P/E TM
--
Dividend
€1.14
Dividend Yield
1.43%
Current Stock Chart for ST JUDE MEDICAL INC (JUD)

st jude medical inc (JUD) Related Businessweek News

View More BusinessWeek News

st jude medical inc (JUD) Details

St. Jude Medical, Inc., together with its subsidiaries, develops, manufactures and distributes cardiovascular medical devices for cardiac rhythm management, cardiovascular, and atrial fibrillation therapy areas worldwide. It operates in two divisions, Implantable Electronic Systems, and Cardiovascular and Ablation Technologies. The company offers tachycardia implantable cardioverter defibrillator systems and cardiac resynchronization therapy defibrillator devices to treat patients suffering from lethal heart conditions, such as sudden cardiac arrest or heart failure. It also provides pacemakers, which deliver low-voltage electrical impulses to stimulate a heartbeat for patients whose hearts beat too slowly; and atrial fibrillation products comprising electrophysiology, introducers and catheters, advanced cardiac mapping, navigation and recording systems, and ablation systems. In addition, the company offers vascular closure devices, compression assist devices, pressure measurement guidewires, diagnostic coronary imaging technology, percutaneous catheter introducers, diagnostic guidewires, renal denervation technology and vascular plugs, optical coherence tomography imaging products, and other vascular accessories, as well as CardioMEMS, a heart failure monitoring device. Further, it provides structural heart products, including transcatheter aortic heart valves, various surgical heart valve repair and replacement products, and transcatheter structural heart defect devices; and neuromodulation products, such as spinal cord stimulation and radiofrequency ablation to treat chronic pain, as well as deep brain stimulation to treat movement disorders. The company sells its products through direct sales force and independent distributors. St. Jude Medical, Inc. was founded in 1976 and is headquartered in St. Paul, Minnesota.

16,000 Employees
Last Reported Date: 02/26/15
Founded in 1976

st jude medical inc (JUD) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.1M
Chief Financial Officer and Vice President of...
Total Annual Compensation: $468.8K
Chief Operating Officer
Total Annual Compensation: $788.3K
President of International Division
Total Annual Compensation: $752.4K
Group President
Total Annual Compensation: $708.5K
Compensation as of Fiscal Year 2014.

st jude medical inc (JUD) Key Developments

St. Jude Medical Inc. Announces FDA Approval of the St. Jude Medical™ Invisible Trial System

St. Jude Medical Inc. announced FDA approval of the St. Jude Medical™ Invisible Trial System. The system, which received CE Mark in June 2015, is fully wireless and leverages Apple™ technology for both the patient and physician controllers. The system is designed to provide patients a more improved and discreet spinal cord stimulation (SCS) trial experience. For many patients, SCS therapy can be an effective option for managing chronic pain. The therapy relies on a small implanted device and thin wires (known as leads) to deliver low levels of electrical energy to mask or interrupt pain signals as they travel along nerve fibers to the brain, which reduces the sensation of pain. Prior to receiving a permanently implanted SCS device, patients undergo a minimally invasive “trial” period to evaluate the therapy. Yet for some patients, complex controllers and bulky programming cables can disrupt the trial experience and act as barrier to SCS therapy. With the Invisible Trial System, St. Jude Medical has removed these barriers, allowing patients to more effectively evaluate their SCS therapy. The system relies on Bluetooth® wireless technology to provide patients a safe, secure and entirely wireless SCS trial experience. Rather than a complex controller, the St. Jude Medical Invisible Trial System provides patients with a more intuitive iPod touch™ digital device as a controller, while physicians will utilize an iPad mini™ digital device to program and evaluate their patient’s therapy. One of the key system features of the St. Jude Medical Invisible Trial System is the use of a small external pulse generator (EPG) as the system’s power source. Because the EPG uses Bluetooth wireless technology to communicate between the patient’s iPod touch controller and the stimulation system, the overall device profile has been reduced so the system can be worn discreetly under a patient’s clothing. The effect is that the system feels essentially “invisible” to the wearer, providing a more comfortable trial experience that allows patients to focus entirely on their system’s therapeutic impact during their trial.

St. Jude Medical, Inc. Announces the Launch of the ILUMIEN III Clinical Trial

St. Jude Medical Inc. announced the launch of the ILUMIEN III clinical trial, a prospective, international, randomized trial evaluating the clinical benefits of the company’s optical coherence tomography (OCT) guidance during stent implantation. The ILUMIEN III study will compare OCT-guided stent implantation to implantation guided by intravascular ultrasound (IVUS) or angiography alone, diagnostic tools that offer less resolution than OCT during intravascular assessments and percutaneous coronary intervention (PCI). The ILUMIEN III study is the multicenter randomized study to date to compare PCI outcomes associated with all three imaging tools. By assessing each diagnostic system head-to-head, the study should offer clear insight into OCT’s ability to influence clinical outcomes. The first patient enrolled within the ILUMIEN III trial was randomized at Columbia University Medical Center and underwent PCI guided by the St. Jude Medical Optis™ Integrated PCI optimization system. During PCI procedures, physicians use diagnostic imaging to make decisions related to stent sizing and to assess how to best keep the artery expanded to restore blood flow to the heart. One key factor in reducing stent failure is increasing the minimal stent area (MSA) and securing appropriate stent expansion during PCI to restore blood flow, a process commonly known as revascularization. Previous research, including findings from the ILUMIEN I and ILUMIEN II studies, has shown that with superior resolution over IVUS and angiography, St. Jude Medical’s OCT imaging technology can influence pre- and post-PCI decision making, stent sizing and deployment. The ILUMIEN III study is the next step in assessing the benefits of OCT guidance in relation to first generation imaging tools. The ILUMIEN III trial aims to enroll up to 420 patients at up to 35 sites across Europe, the U.S. and Japan. All patients will undergo PCI for stable or unstable angina (chest pain caused by insufficient blood flow to the heart), silent ischemia (restricted blood flow to the heart that causes no chest pain), or patients who’ve suffered NSTEMI or STEMI heart attacks due to arterial blockages. Patients will be randomized to undergo PCI with either OCT, angiography or IVUS and the primary endpoint will be the degree of minimum stent area achieved. Physicians assessing patients in the ILUMIEN III study will employ the St. Jude Medical Optis Integrated and ILUMIEN™ Optis™ PCI optimization systems to assess patients randomized to OCT-guided stent implantation.

St. Jude Medical Inc. Presents at Medical Device Conference 2015, Jun-26-2015 01:10 PM

St. Jude Medical Inc. Presents at Medical Device Conference 2015, Jun-26-2015 01:10 PM. Venue: Palace Hotel, 2 New Montgomery Street, San Francisco, California, United States. Speakers: Eric S. Fain, Group President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JUD:GR €66.97 EUR -0.90

JUD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $17.34 USD +0.09
CR Bard Inc $196.65 USD +3.55
Olympus Corp ¥4,750 JPY +5.00
Smith & Nephew PLC 1,189 GBp +22.00
Zimmer Biomet Holdings Inc $104.07 USD -0.78
View Industry Companies
 

Industry Analysis

JUD

Industry Average

Valuation JUD Industry Range
Price/Earnings 20.6x
Price/Sales 3.8x
Price/Book 5.5x
Price/Cash Flow 18.4x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ST JUDE MEDICAL INC, please visit www.sjm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.